Os conhecimentos actuais da patologia molecular do cancro do pulmão requerem outra caracterização histológica, para além de carcinoma de células pequenas e carcinoma não pequenas células para suporte da terapia personalizada e entendimento do valor real dos fármacos actualmente disponíveis. Como o diagnóstico e seguimento clínico da maioria dos casos de cancro do pulmão se baseia em produtos de biópsia e citologia, a classificação imunoistoquími-ca do carcinoma broncopulmonar (IBPCC) é necessá-ria para suporte morfológico da classificação da WHO 1999/2004, clarificando as características celulares das neoplasias e o entendimento da carcinogénese.
Introduction
Pathology is far from what it can be considered as to have been its beginning in the XVIII century by the first descriptions of Morgagni and further by Virchow with the use of the microscope. What is important to have in mind is the fact that the survival age was in the thirties years of age, even from the time of Hippocrates, Celsius and Galen. The Egyptians left their papyrus, namely Ebers´ (Amenhotep Kingdom 1557 -1501BC) with exhaustive reports of infections and tumours, although benign, but related to the different parts of the body. Medicine began at Cos School in Greece (500BC), from where the Corpus Hipocra ticus emanated, followed by the De Artibus of Aulus Cornelius Celsius from Verona -Italy. The Arabs had the possibility to ensemble the two knowledges while divagating around the Mediterranean during their struggles, making then a wealthy synthesis gathering also the Persian and Indian know ledge. Kanum is really a joint canon made then by Ibis Sina/ Avicena (980-1037). By then confidence was achieved in recogni zing malignant tumours and metastasizing 1 . The actual known scientific method comes in the catholic/medieval time with Galileo (1564-1634) and Kepler (1571-1635), succeeding Copernicus (1473) and having as starting point the greec-italian-arab-indu knowledge since the Salerno School (XI century). The Magister Salernus as we get to know today was probably written by a Jew, an Arab, a Greek and a Christian. The Tumoribus Praeter Naturum written by Gabriel Falopius (1523-1562) is the first pathology book and the microscope used by Malpighi (1562-1682) helped in rooting the anatomy bases. Histology encased in between by the eyes of Bichat (1771-1802) together with anatomy and pathology, reinforced by René Laennec (1781-1826). The expertise of Rudolf Virchow (1821-1826) with an acromatic microscope (1830) brought the zell/cell to the medical practice [1] [2] [3] . This way we get to the contemporary medicine we can consider to have its beginning in 1953 with the DNA double helix of Watson and Creek and in fifty years we jumped into the molecular pathology and modern medicine with a huge advance in disease therapy, gathering all technical methodologies now available. At this point is the demanding diagnosis of bronco-pulmonary carcinoma made on small biopsies (or a couple of cells) submitted to the WHO 1999/2004 classification [4] [5] . We owe to the Sweden doctor Leiv Kreyberg the first histological characterization of bronchial-pulmonary carcinomas done in 1954 after studying carbon mines workers. These patients exhibited the illnesses dependent on mines environment: carbon lung and silicosis together with tuberculosis and developing lung cancer very frequently. Smoking accelerated the incidence of lung cancer as we know today. In 1967, the Organisation Mondiale de la Santé supported the first work directed to the standardization of tumoural nomenclature adapted to each organ to discipline Pathologists that frequently renamed differently the same lesion. Types Histologiques des Tumeurs du Poumon was the blue book number 1 of the WHO blue book series directed to the histological classifications of neoplasias in each organ 2, 6 . The incidence of lung cancer is far from diminishing its incidence although the habit of smoking is clearly decreasing and still 60 to 70% of new lung cancer cases are diagnosed in non surgical stages with 10 to 12 months probability of survival. This situation and the poverty of survival rates achieved with the possible therapy conducting to a high mortality raised the general histological reference of small cell carcinoma and non small cell carcinoma in Pathologists´ reports as the first histological type meant non surgical behaviour because of very poor prognosis compared with the other types. As molecular pathology is developing towards predictive therapy which means personalized choice dependent on carcinoma histological type and quite defined particularities, the diagnosis has to be made with approximate precision in the small biopsies obtained by endobronchial examination, transthoracic biopsies and even in groups of small number of neoplastic cells of cytological methods [7] [8] [9] [10] . The use of immunohistochemial antibodies and the experience acquired in reporting lung cancer in surgical specimens based in total inclusion in paraffin of tumours, have conducting either to WHO classification and to the Reclassificação do carcinoma broncopulmonar: diferenciação do tipo histológico em biópsias por imuno-histoquímica Lina Carvalho recognition of the possible different patterns of bronchial-pulmonary carcinomas that can be explored in small biopsies 11, 12 .
Lung cancer classifications till WHO 1999/2004
The morphological descriptions of lung carcinomas have been refined since Kreyberg and the OMS/1967 classification with maintenance of the histological types, firstly described in five groups, revealing a large heterogeneity recognized ab initio: 16 . The other patterns and poorly differentiated epidermoid carcinoma -not exhibiting keratinisation and justifying the title of epidermoid carcinoma instead of squamous cell carcinoma -require use of IHC 17, 18 . High-weight-molecular cytokeratins (HWMC -LP34/34βE12/…) are of daily use as adenocarcinomas of the bronchus or of the lung do not express those keratins that are expressed by metaplastic pavimentoid cells in respiratory epithelium, where normally a clear basal cell positive layer is distinctly defined till the epithelium of the bronchioles where it is absent ( Fig. 1 ). Also TTF1 (Thyroid Transcription Factor 1) and CK7 are consistently negative in epidermoid carcinomas and if positive, the heterogeneity of cell types has to be considered and reported to make the diagnosis of combined small cell carcinoma or adenosquamous carcinoma and then validate therapy and prognosis 19 . The basaloid variant can only be reported as a pattern if no keratinisation is present as the basaloid carcinoma included in the large cell carcinoma group has poorer prognosis. CK7 may be expressed together with HWMC in these carcinomas and their rarity has also to be kept in mind. Small cell variant of epidermoid carcinoma has become easily recognisable when TTF1 and Ki67 proliferation marker are searched together with HWMC. A Ki67 proliferation index higher than 80% together with clear expression of HWMC indicates a combined small cell carcinoma and epidermoid carcinoma; TTF1 may show the same quantity of nuclear expression or lower in this situation. The WHO classification does not embrace the cellular capacities determined by IHC in small pieces of tissue as it has been done considering surgical specimens where poor- Reclassificação do carcinoma broncopulmonar: diferenciação do tipo histológico em biópsias por imuno-histoquímica
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ly differentiated areas of carcinomas were not considered to be reported and not explored as it would have made a much more complex classification -the 10% law 20 .
Adenocarcinoma
Heterogeneity of primary bronchial-pulmonary adenocarcinomas and also of sarcomatoid and large cell carcinomas of the lung is related to embryology and multiple bronchial -pulmonary cell types with different functions are now under the explanation of the epithelial mesenchimal transition (EMT) theory 21 .
As referred for squamous cell carcinoma, HWMCs delineate the basal cell bronchial layer till bronchioles where ciliated cells continue to express CK7 and alveolar cells, CK7 and TTF1 focally. Cell types vary from cuboidal to columnar, with either variable mucinous cytoplasm and basal or hobnail nuclei [22] [23] [24] . The expression of CK20 by adenocarcinomas has to be related with the common embryological origin of upper and lower airways together with anterior intestine as it does not occur in mature respiratory epithelium. These primary carcinomas when expressing CK7 without TTF1, define intestinal carcinomas and having histogenetical dependence from respiratory epithelium might well be called bronchial adenocarcinomas 25, 26 . [31] [32] [33] . Terminal respiratory unit adenocarcinoma described by Noguchi do not overtake 3cm diameter, has central desmoplastic stroma with tumoural acinar pattern, surrounded by papillary, micropapillary, acinar or nonmucinous BAC, keeping fidelity to CK7 and TTF1 nuclear expression and negativity to the other IHC markers (Fig. 3 ) [34] [35] . The above referred theory is extended to larger adenocarcinomas where less organized patterns are present and then the TTF1 nuclear expression may be lost while CK7 is constant and this event has to be taken as very important when reporting bio psies as the less differentiated patterns determine a poorer prognosis and are often gathered in lymphatic vessels of bronchial biopsies 36, 37 . Differential diagnosis with mesothelioma keeps being a challenge when clinicians forget to refer pleural expansion without the presence of a definite mass and after reporting adenocarcinoma CAT does not show the tumour. The classical pseudo-mesotheliomatous adenocarcinoma has become rare. Nowadays calretinin keeps being the most reliable antibody for malignant mesothelial cells together with cytokeratins (CK5/6 or CK7) to mark spindle mesotheliomatous cells. The use of anti-glicoproteins antibodies as CEA and Ber-EP4 is needed to discard adenocarcinoma and cytoplasmic membrane reinforcement by EMA in malignant mesothelial cells is reliable [38] [39] [40] [41] . BAC keeps being controversial as considered an in situ carcinoma in WHO classification and then reported with metastases in some series. Nonetheless atypical adenomatous hyperplasia is the preinvasive lesion of non-mucinous type that is also the pattern found in mixed type adenocarcinoma while pure mucinous BAC is multifocal and often bilateral. The mixed non-mucinous and mucinous type is seen in larger lesions when desmoplastic reaction is present with acinar invasion and then related to lymph node metastases. This last situation is no more a BAC in WHO classification but a mixed type adenocarcinoma 42 . The IHC expression of BAC is also variable as limited to CK7 and TTF1 in non-mucinous type and revealing CK20 and scarcity of CK7 and no TTF1 in some cases of mucinous BAC. This IHC pattern can be related to an intestinal mucinous BAC that can be multifocal and distinct from bronchial adenocarcinoma (Fig. 4) 43 .
No descriptions are available till now to distinguish gender patterns and it is well stated that pulmonary adenocarcinomas in women have a better prognosis. The feminine adenocarcinomas may show particular patterns as hepatoid pattern and oestrogen, progesterone and variable cytoplasmic membrane glicoproteins IHC expression. When in small biopies an endometrioid pattern is suggested (Fig. 5) .
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ning a classification as si mple as the categories of IHC antibodies expressed, assumed in a small panel useful to define the platform for predictive therapy [44] [45] [46] [47] [48] .
Neuroendocrine tumours
Depending on patient age different small cell tumours raise differential diagnosis solved by IHC and complementary analysis to distinguish from small cell carcinoma. For this histological type, after nuclear crushing artefact, Ki67 proliferation index is the most reliable marker revealing more than 80% positive malignant nuclei. The alveolar cell maker TTF1 is also expressed by these tumours but not consistently. While chromogranin and synaptophisin expression are constant in carcinoids, CD56 is more prone to small cell carcinoma 49, 50 . Small cell carcinoma is keratin temperamental varying the expression from null till high expression of HWMC or CK7. In these cases a combined small cell carcinoma and squamous cell carcinoma or adenocarcinoma has to be taken in mind in small biopsies and careful attention given to bronchial epithelium that may reveal also positive TTF1 and Ki 67 dysplasia (Fig. 6) 51, 52 . Neuroendocrine carcinomas in the lung concern typical and atypical carcinoids and large cell neuroendocrine carcinoma beyond small cell carcinoma and histological criteria are clearly defined in the WHO 2004 classification. It is important to recognize typical carcinoid lymph node metastases as this may occur till 14% of the cases 53, 54 . The thyroid transcription factor 1 was also found in type II pneumocytes and connects an adenocarcinoma to the lung but also characterizes small cell carcinoma. Usually carcinoids do not express that factor that has also been understood as a proliferation marker. The proliferation index validated by Ki67 in small and artefactual biopsies is mandatory to distinguish typical and atypical carcinoid (<4-10%), large cell neuroendocrine carcinoma (20-50%) and small cell carcinoma (>80%) together with neuroendocrine markers usually 55, 56 .
Adenosquamous carcinoma
Not many concern has been given to this pulmonary carcinoma but in small biopsies it is common to have HWMC and CK7 expression in neoplastic cells. When carefully observed it is possible to see in the pavementous/epidermoid cellular clusterings, luminal drafts with both different expression and patterns of those cytokeratins. This way adenosquamous carcinoma may present in a spectrum from a well differentiated type to moderately differentiated and poorly differentiated types keeping the expression of CK7 and HWMC in separate and/or in the same cells, with combined patterns. Usually TTF1 is absent but if pre- Reclassificação do carcinoma broncopulmonar: diferenciação do tipo histológico em biópsias por imuno-histoquímica Lina Carvalho sent the cell type has to be considered to raise the possibility of a combined small cell or a TRU adenosquamous carcinoma, depending on Ki67 nuclear rate 57 . It has to be kept in mind that salivary gland tumours have epidermoid and glandular patterns that are not mistaken for adenosquamous carcinomas. Also the cam5.2 marker and androgen and oestrogen receptors are expressed in those tumours.
Pleomorphic carcinomas
The confidence in IHC to classify bronchial -pulmonary carcinomas is defined in Ta Reclassificação do carcinoma broncopulmonar: diferenciação do tipo histológico em biópsias por imuno-histoquímica
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nosis and histogenesis in future. By now, vimentin, desmin and smooth muscle actin have to be expressed (one positive antibody is sufficient) to define a pleomorphic carcinoma independently of the observed histological patterns 58 .
Discussion
The Pathologist concern is beyond the diagnosis of non-small cell or small cell carcinoma when reporting small biopsies or cytology specimens and IHC became an easy and useful tool. Cell morphology and histological types and patterns are leaders of reporting and rationalize the choice of limited IHC panel. This concern goes further than diagnosis as important therapeutic drugs are revealing prognostic value based in bronchial and pulmonary carcinoma histology [59] [60] [61] [62] . The IHC panel defined in Table I and quoted in the proposed immunohistochemical 
SQC -squamous cell carcinoma SCC -small cell carcinoma ADC -adenocarcinoma BAC -bronchioloalveolar carcinoma TRU -terminal respiratory unit LCC -large cell carcinoma LCNEC -large cell neuroendocrine carcinoma ADSC -adenosquamous carcinoma C -carcinoma VMT -vimentin
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bronchial-pulmonary carcinoma grouping/ /classification -IBPCC -in Table II is widely used as the applied antibodies are reliable and easily validated. The usefulness of the presenting IBPCC relies in its simplicity of understanding cell types and cellular potentialities either in bronchial cylindrical and ciliated epithelium and also in carcinomas arising in the TRU unit or when presenting as solid tumours of heterogeneous patterns and cellularity. This work may be a refining of the attempt made by Dr Edwards in 1987 when ICM was not so accessible 63 . The IBPCC raises from the knowledge acquired in reporting surgical specimens after observing loads of slides of the whole sectioned tumour. An adenocarcinoma of the lung does not express HWMC and even in the hilum where intestinal adenocarcinomas develop more frequently, CK20 and CK 7 are exclusive with a variability of the nuclear presence of TTF1. Also when acinar and/or papillary paterns are present in a small biopsy the expression of TTF1 and CK20 persist in the surgical specimen where complementing patterns of a mixed adenocarcinoma show up. BAC is a challenging group of tumours whose macroscopy and histology has not yet been definitely corroborated. The mucinous type expressing CK20 and non-mucinous type with hobnail and Clara cells expressing CK7 and TTF1, with mixed types in between, as prone intestinal type with mucinous papillae or as gathering CK20, CK7 and TTF1 expression, have different therapeutical, staging and prognostic effects. The first group known to be multifocal and with bilateral potentiality and the other types more often an unique mass, with or without central desmoplasia, defy the WHO criteria. 64, 65 . The mesenchimal antibodies more often used are vimentin, actin and desmin that are not expressed in adenocarcinomas, neuroendocrine carcinomas and epidermoid differentiating carcinomas. Better than considering two independent groups of large cell carcinoma and sarcomatoid carcinoma, still subdivided, or quote them together as poorly differentiated carcinomas, an unique group of pleomorphic carcinoma (Table II) shows to be either comprehensive and fea- 39 . At the bottom of the group carcinosarcoma and blastoma polarize epithelial to mesenchimal transiton theory for carcinogenesis and embryogenesis potentiality respectively. Spindle cell and giant cell patterns reinforce the cellular level capacities and the IBPCC already discussed 67, 68 . The IBPCC is a useful tool as molecular pathology is coming to the pathologist bench demanding accurate morphology recognition based in small tissue or cell samples dependent on an IHC panel that has to be reported having in mind reliable prognosis outcome 69, 70 .
Predictive therapy is already a reality in some pulmonary pathology centres and it is a result of trials that gather therapy, gene expression and/or mutations and prognosis. Still the commoner applied language is small cell carcinoma and non-small cell carcinoma with already cellular morphological and immunohistochemical bias. In the application and distinction between clinical outcomes from the applied therapies, first and second lines, a second biopsy may become mandatory to revalidate cellular characteristics to predict therapy answer 39, 71, 72 .
Still an enormous effort has to be done in order to understand the multidirectionality importance of each morphological pattern in each histological type of lung cancer when observing surgical specimens by descending to molecular level. After this laborious task more knowledge will be brought to cellular level characterization when diagnosing in small samples or neoplastic cells [73] [74] [75] [76] . The complementary or primordial approach may reside in the neoplastic cells 
